Lamivudine/nevirapine/zidovudine

Lamivudine/nevirapine/zidovudine
Combination of
Lamivudinenucleoside reverse transcriptase inhibitor
Nevirapinenon-nucleoside reverse transcriptase inhibitor
Zidovudinenucleoside reverse transcriptase inhibitor
Names
Trade namesDuovir-N, Zidovex-LN, others[1]
Clinical data
WHO AWaReUnlinkedWikibase error: ⧼unlinkedwikibase-error-statements-entity-not-set⧽
Defined daily dosenot established[2]

Lamivudine/nevirapine/zidovudine (3TC/NVP/AZT) is a fixed-dose combination medication used to treat HIV/AIDS.[3] It contains lamivudine, nevirapine, and zidovudine.[3] It is either used by itself or along with other antiretrovirals.[3] It is a recommended treatment in those who are pregnant.[3] It is taken by mouth twice a day.[3]

The medication is generally well tolerated.[1] Side effects are those of the underlying medications.[3] This includes rash, pancreatitis, low white blood cell levels, and muscle pain.[1] Use is not recommended in those with significant liver problems.[1] Use in pregnancy and breastfeeding appear to be safe.[1] The combination tablet is typically not appropriate for children.[3]

It was on the World Health Organization's List of Essential Medicines; however, was removed.[4][5] The wholesale cost in the developing world is about 8 to 19 USD a month as of 2014.[6] The combination is not commercially available in the United States as of 2018.[7]

Dosage

The defined daily dose is not established[2]

See also

References

  1. 1 2 3 4 5 "Nevirapine, zidovudine and lamivudine" (PDF). aidsmap. Archived from the original (PDF) on 20 December 2016. Retrieved 18 December 2016.
  2. 1 2 "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 9 August 2020. Retrieved 18 September 2020.
  3. 1 2 3 4 5 6 7 World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. pp. 157, 161. hdl:10665/44053. ISBN 9789241547659.
  4. ↑ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  5. ↑ "Additions and deletions of medicines on the WHO model lists of essential medicines: 1977-2017". WHO. Archived from the original on 8 July 2023. Retrieved 15 September 2023.
  6. ↑ "Lamivudine + Zidovudine + Nevirapine". International Drug Price Indicator Guide. Archived from the original on 22 January 2018. Retrieved 8 December 2016.
  7. ↑ "Drugs@FDA: FDA Approved Drug Products". www.accessdata.fda.gov. Archived from the original on 28 June 2017. Retrieved 6 January 2018.
Identifiers:
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.